A Study Of PF-04449913 Administered Alone In Select Solid Tumors

A PHASE 1 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF PF 04449913, AN ORAL HEDGEHOG INHIBITOR, ADMINISTERED AS SINGLE AGENT IN SELECT SOLID TUMORS

This study examines the effect of a small molecule inhibitor to the Sonic Hedgehog pathway on select solid tumors.

Inclusion Criteria:

• Histological or cytological diagnosis of advanced/metastatic solid tumor
• Adequate Bone Marrow Function
• Adequate Renal Function
• Adequate Liver Function

Exclusion Criteria:

• Patients with known symptomatic brain metastases requiring steroids
• Current active treatment on another clinical trial
• Major surgery or radiation therapy within 4-weeks of starting study treatment